Michelson Medical Research Foundation’s iShares S&P 500 Value ETF IVE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$11.8M Hold
51,905
10.89% 1
2026
Q1
$11M Hold
51,905
11.13% 2
2025
Q4
$11M Hold
51,905
11.03% 2
2025
Q3
$10.7M Hold
51,905
9.32% 4
2025
Q2
$10.1M Hold
51,905
9.73% 4
2025
Q1
$9.89M Hold
51,905
8.28% 5
2024
Q4
$9.91M Hold
51,905
8.3% 2
2024
Q3
$10.2M Hold
51,905
7.21% 3
2024
Q2
$9.45M Hold
51,905
8.12% 3
2024
Q1
$9.7M Hold
51,905
5.88% 6
2023
Q4
$9.03M Hold
51,905
5.95% 5
2023
Q3
$7.99M Hold
51,905
5.39% 6
2023
Q2
$8.37M Hold
51,905
5.95% 8
2023
Q1
$7.88M Sell
51,905
-41,180
-44% -$6.22M 6.18% 6
2022
Q4
$13.5M Buy
+93,085
New +$13.3M 8.75% 4

Other funds holding IVE

Michelson Medical Research Foundation's IVE Position: Q2 2026 in Review

Michelson Medical Research Foundation held its iShares S&P 500 Value ETF (IVE) position steady in Q2 2026 at 51,905 shares worth $11.8M. The position accounts for 10.89% of the portfolio, ranked #1.

Michelson Medical Research Foundation first reported a position in IVE in Q4 2022 and has held it in 15 quarters since. The position peaked at $13.5M in Q4 2022. 1,763 funds tracked by Wall St. Rank hold IVE as of Q2 2026.

  • Michelson Medical Research Foundation held 51,905 shares of iShares S&P 500 Value ETF worth $11.8M as of Q2 2026.
  • Michelson Medical Research Foundation left its iShares S&P 500 Value ETF share count unchanged in Q2 2026.
  • iShares S&P 500 Value ETF made up 10.89% of Michelson Medical Research Foundation's portfolio in Q2 2026, its #1 holding.
  • Michelson Medical Research Foundation first reported a position in iShares S&P 500 Value ETF in Q4 2022 and has held it in 15 quarters since.
  • Michelson Medical Research Foundation's iShares S&P 500 Value ETF position peaked at $13.5M in Q4 2022.
  • 1,763 funds tracked by Wall St. Rank held iShares S&P 500 Value ETF as of Q2 2026.

Based on Michelson Medical Research Foundation's 13F filing for Q2 2026, filed 14 Aug 2026.